BCRX

SEC source: 0001127602-21-008761 · form4.xml · nonDerivative · entry 1

Hutson Nancy J · CIK 0001379222 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,756

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-21-008747 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,496

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-21-007642 · form4.xml · derivative · entry 3

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 41,250 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-007642 · form4.xml · nonDerivative · entry 2

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,475

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $11.50 to $11.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-21-007642 · form4.xml · nonDerivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.

SEC source: 0001127602-21-007295 · form4.xml · derivative · entry 3

Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-21-007295 · form4.xml · nonDerivative · entry 2

Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,156

F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.

SEC source: 0001127602-21-007295 · form4.xml · nonDerivative · entry 1

Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-20-031803 · form4.xml · derivative · entry 1

Sniecinski Megan · CIK 0001781480 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031800 · form4.xml · derivative · entry 1

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031795 · form4.xml · derivative · entry 1

Gayer Charles K · CIK 0001800110 · Vice President and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031791 · form4.xml · derivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Stock · 280,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031788 · form4.xml · derivative · entry 1

Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,000

Underlying: Common Stock · 280,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% of each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031782 · form4.xml · derivative · entry 1

Doyle Anthony · CIK 0001808688 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,500

Underlying: Common Stock · 332,500 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031786 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,000

Underlying: Common Stock · 335,000 shares

Expires 2030-12-15

F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031780 · form4.xml · derivative · entry 4

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 870,000

Underlying: Common Stock · 870,000 shares

Expires 2030-12-15

F3 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-20-031780 · form4.xml · derivative · entry 3

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 134,278 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020.

SEC source: 0001127602-20-031780 · form4.xml · nonDerivative · entry 2

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 784,086

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.18 to $8.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-20-031780 · form4.xml · nonDerivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 918,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020.

SEC source: 0001127602-20-031406 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,741 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,061

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.95 to $7.97. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-20-031406 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001127602-20-030837 · form4.xml · derivative · entry 3

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,741

Underlying: Common Stock · 13,741 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 2

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,061

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.22 to $6.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-20-030837 · form4.xml · nonDerivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,802

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001127602-20-030706 · form4.xml · derivative · entry 1

Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-030704 · form4.xml · derivative · entry 1

Sheridan William P · CIK 0001439174 · Senior VP - CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-030700 · form4.xml · derivative · entry 1

Barnes Alane P · CIK 0001584348 · Senior VP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-030696 · form4.xml · derivative · entry 1

Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-030693 · form4.xml · derivative · entry 2

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,250

Underlying: Common Stock · 157,250 shares

Expires 2029-12-17

F2 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020.

SEC source: 0001127602-20-030693 · form4.xml · derivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2023-08-08

F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020.

SEC source: 0001127602-20-030291 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,386

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-030289 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,569

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-030287 · form4.xml · nonDerivative · entry 1

Hutson Nancy J · CIK 0001379222 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,293

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-030285 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,274

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750.

SEC source: 0001127602-20-024646 · form4.xml · nonDerivative · entry 1

Hutson Nancy J · CIK 0001379222 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,315

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-024644 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,408

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-024642 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,613

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-024637 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,605

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750.

SEC source: 0001127602-20-023449 · form4.xml · nonDerivative · entry 1

Doyle Anthony · CIK 0001808688 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,000

SEC source: 0001127602-20-018719 · form4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,204

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-018715 · form4.xml · nonDerivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,204

F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.

SEC source: 0001127602-20-018711 · form4.xml · nonDerivative · entry 1

Hutson Nancy J · CIK 0001379222 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,111

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000

SEC source: 0001127602-20-018704 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,087

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $18,750.

SEC source: 0001127602-20-016759 · form4.xml · derivative · entry 1

Stonehouse Jon P · CIK 0001385496 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,250

Underlying: Common Stock · 157,250 shares

Expires 2029-12-17

F1 · date: On May 13, 2020, the Board of Directors determined that the initial data from part 3 of the BCX9930 phase 1 clinical trial represented successful results from a proof of concept study of BCX9930 and, as a result, that one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020.

SEC source: 0001127602-20-016584 · form4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

SEC source: 0001127602-20-016580 · form4.xml · derivative · entry 1

LEVIN ALAN G · CIK 0001174452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

SEC source: 0001127602-20-016575 · form4.xml · derivative · entry 1

LEE KENNETH B JR · CIK 0001208570 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

SEC source: 0001127602-20-016571 · form4.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

SEC source: 0001127602-20-016565 · form4.xml · derivative · entry 1

HEGGIE THERESA · CIK 0001760020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.